Which group of people is Pazopanib mainly suitable for?

Pazopanib is a targeted therapy drug that is a tyrosine kinase inhibitor (TKI). It mainly exerts anti-tumor effects by inhibiting multiple targets such as vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR). It achieves the effect of anti-tumor treatment by blocking the blood supply of tumor cells and inhibiting tumor growth factors. Pazopanib is mainly used to treat patients with certain types of renal cancer, soft tissue sarcoma and other tumors, especially for patients with advanced or metastatic tumors. It can effectively prolong survival and improve quality of life.

The broadest indication for pazopanib is the treatment of advanced or metastatic renal cell carcinoma (RCC). For such patients, pazopanib, as a targeted therapy, can effectively inhibit the angiogenesis of tumor cells, reduce the blood supply to the tumor, and thereby inhibit the growth and spread of the tumor. In many clinical studies, pazopanib has shown significant efficacy, effectively delaying the progression of renal cancer and improving patients' progression-free survival (PFS). Pazopanib is often used as a second-line treatment, especially in patients whose disease has progressed despite other treatments, such as chemotherapy or immunotherapy.

In addition to renal cell carcinoma, pazopanib is also used to treat certain types of soft tissue sarcoma (STS). Soft tissue sarcomas are malignant tumors arising from connective tissue or muscle tissue and usually present as localized lumps or pain. For these patients, pazopanib provides an effective targeted treatment option, especially when conventional treatments such as surgery or radiation therapy fail to fully control the disease. Pazopanib can effectively inhibit tumor growth through its multi-target mechanism of action, and is better tolerated and has fewer side effects than traditional chemotherapy regimens.

Pazopanib is suitable for patients who cannot undergo surgery or radiotherapy, especially those with metastatic or recurrent tumors, and its anti-tumor effect has been widely verified. Pazopanib offers an effective targeted treatment option for patients with renal cancer and soft tissue sarcomas, especially those who are older or have poorer medical conditions. When treated with pazopanib, patients need to undergo regular examinations, especially monitoring of liver function and cardiovascular health, because the drug may cause side effects such as high blood pressure, abnormal liver function, and rash.

References：https://www.votrient.com/